Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference

(NASDAQ:LSTA), BASKING RIDGE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will present a corporate […]

GlobalFoundries Announces Leadership Transition to Drive Next Phase of Growth

(NASDAQ:GFS), MALTA, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) — GlobalFoundries (Nasdaq: GFS) (GF) today announced, following a rigorous succession planning process, its Board of Directors has appointed Dr. Thomas Caulfield as Executive Chairman and Tim Breen as Chief Executive Officer. Caulfield succeeds Ahmed Yahia who will step down from the Board and his role as

UAV Corp (UMAV) Kicks Off Landmark “SKY” Hangar Project with Land Clearing at Costin Airport Setting Stage for Q1 2025 Groundbreaking

(OtherOTC:UMAV),(OTC US:UMAV), WEWAHITCHKA and PORT ST JOE, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) — UAV Corp (OTC: UMAV) is making significant strides toward its visionary SKY Hangar project, with land clearing now officially underway at its wholly owned Costin Airport. This marks the first major step toward the Q1 2025 groundbreaking of a cutting-edge facility

Giftify, Inc. Cancels Equity Line of Credit

(NASDAQ:GIFT), SCHAUMBURG, IL, Feb. 05, 2025 (GLOBE NEWSWIRE) — Giftify, Inc. (NASDAQ: GIFT) (the “Company”), the owner and operator of leading digital platforms, CardCash.com and Restaurant.com, with a focus on incentives and rewards in retail, dining & entertainment experiences, today announced the cancellation of its equity line of credit (ELOC). On December 16, 2024, the

Gain Therapeutics To Participate in Upcoming Investor Conferences

(NasdaqGM:GANX), BETHESDA, Md., Feb. 05, 2025 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, Chief Executive Officer of Gain, will present at two upcoming investor conferences: BIO CEO

Fluent, Inc. Survey Finds That Shoppers Embrace Post-Purchase Ads, Citing Personalization & Relevance as Key Benefits

(NASDAQ:FLNT), NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) — Fluent, Inc. (NASDAQ: FLNT), a leading commerce media solutions company, today released the results of a new survey revealing how post-purchase ads enhance the shopping experience, drive product discovery, and encourage repeat purchases. Post-purchase ads, which appear on ecommerce confirmation pages, are designed to keep shoppers

Community Housing Capital and Federal Home Loan Bank of Atlanta Award $750,000 for Affordable Housing in Southfield

SOUTHFIELD, Mich., Feb. 05, 2025 (GLOBE NEWSWIRE) — Community Housing Capital (CHC) and the Federal Home Loan Bank of Atlanta (FHLBank Atlanta) announced today an investment of $750,000 in grant funding designated for John Grace Arms, a project to construct 60 multifamily rental units in Southfield, Michigan. The funding, sourced from FHLBank Atlanta's Affordable Housing

Duolingo to Participate in Upcoming Investor Conferences

(NASDAQ:DUOL), PITTSBURGH, Feb. 05, 2025 (GLOBE NEWSWIRE) — Duolingo, Inc. (Nasdaq: DUOL) announced participation at the following investor conferences: Morgan Stanley Technology, Media and Telecom Conference on Monday, March 3rd Citizens JMP Technology Conference on Tuesday, March 4th (Fireside Chat at 2:00 pm PT) KBCM Emerging Technology Summit on Wednesday, March 5th (Fireside Chat at

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

(NASDAQ:MYGN), SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to integrate Myriad's advanced molecular diagnostic tests — Prolaris(R) Prostate Cancer Test and MyRisk(R) Hereditary Cancer

Lantheus Announces Presentations Featuring PYLARIFY (Piflufolastat F 18) Data at the ASCO GU Meeting

(NasdaqGM:LNTH), Data highlights PYLARIFY's ability to detect recurrent prostate cancer in patients with low PSA Real-world evidence of PYLARIFY's effectiveness in prostate cancer being presented BEDFORD, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to

Scroll to Top